Media stories about Neothetics (NASDAQ:NEOT) have trended positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neothetics earned a news sentiment score of 0.32 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.0804960018565 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Separately, ValuEngine downgraded Neothetics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 27th.

Neothetics (NEOT) traded down 9.1852% during trading on Friday, hitting $0.3678. The stock had a trading volume of 566,910 shares. Neothetics has a one year low of $0.30 and a one year high of $2.63. The firm has a 50 day moving average of $0.46 and a 200-day moving average of $1.42. The company’s market cap is $5.09 million.

Neothetics (NASDAQ:NEOT) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). Equities analysts anticipate that Neothetics will post ($0.61) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/27/favorable-press-coverage-somewhat-unlikely-to-impact-neothetics-neot-share-price.html.

Neothetics Company Profile

Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.

Insider Buying and Selling by Quarter for Neothetics (NASDAQ:NEOT)

Receive News & Stock Ratings for Neothetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neothetics Inc. and related stocks with our FREE daily email newsletter.